The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved. Zepbound is approved to treat obesity and Mounjaro ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

Bruker Corporation today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also ...

The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.

Overview of the Migraine Drugs MarketThe global Migraine Drugs Market is valued at $6.37 billion in 2024 and is projected to ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

US president Donald Trump has only been back in office for just over a month, but he is already engaging in trade wars with ...

Experts noted that rapid and extreme weight loss can introduce unique risks, such as a weakened immune system and malnourishment, as well as potentially too much muscle loss. They’re also concerned ...

During the fourth quarter, the Harbor Capital Appreciation Fund returned 6.22%, underperforming its benchmark, the Russell ...